Size | Price | |
---|---|---|
1mg | ||
2mg | ||
5mg | ||
10mg | ||
25mg | ||
50mg |
MRS2279 is a potent, selective and competitive antagonist of the P2Y1 receptor with a Ki of 2.5 nM and an IC50 of 51.6 nM. MRS2279 potently inhibits ADP-induced aggregation of human blood platelets in vitro (pKB = 8.05).
ln Vitro |
MRS2279 inhibits the production of phosphoinositides in turkey erythrocyte membranes when 2-MeSADP is added, with a pKb value of 7.75 [2]. In 1321N1 human astrocytoma cells, MRS2279 exhibits high-affinity competitive antagonism to the human P2Y1 receptor with a pKb value of 8.10 [2]. Human P2Y2, P2Y4, P2Y6, and P2Y11 receptor cognate agonist activation is unaffected by MRS2279, however it has a distinct effect on the P2Y1 receptor [2]. It has not been shown that MRS2279 can prevent the build-up of cyclic AMP by obstructing ADP via platelet Gi/adenylate cyclase-linked P2Y receptors [2].
|
---|---|
ln Vivo |
In mice receiving high-pressure ventilation, MRS2279 (2 μL, 1 nM; intracerebroventricular injection; 30 minutes prior to mechanical ventilation) can lessen brain damage brought on by mechanical ventilation [3].
|
References |
[1]. Nandanan E, et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem. 2000;43(5):829-842.
[2]. Boyer JL, et al, Ravi RG, Jacobson KA, Harden TK. 2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol. 2002;135(8):2004-2010. [3]. Wei W, et al. Mechanical ventilation induces lung and brain injury through ATP production, P2Y1 receptor activation and dopamine release. Bioengineered. 2022 Feb;13(2):2346-2359. |
Molecular Formula |
C13H20CLN5O8P2
|
---|---|
Molecular Weight |
469.71132
|
CAS # |
367909-40-8
|
Related CAS # |
MRS2279 diammonium;2387505-47-5
|
SMILES |
O=P(O)(O[C@@H]1[C@@H](COP(O)(O)=O)C[C@@H](CN2C=NC3=C(NC)N=C(Cl)N=C23)C1)O
|
InChi Key |
LPZJKPSGEADHTQ-HLTSFMKQSA-N
|
InChi Code |
InChI=1S/C13H20ClN5O8P2/c1-15-11-10-12(18-13(14)17-11)19(6-16-10)4-7-2-8(5-26-28(20,21)22)9(3-7)27-29(23,24)25/h6-9H,2-5H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t7-,8-,9+/m1/s1
|
Chemical Name |
[(1S,2R,4R)-4-[(2-chloro-6-methylaminopurin-9-yl)methyl]-2-(phosphonooxymethyl)cyclopentyl] dihydrogen phosphate
|
Synonyms |
MRS2279 MRS-2279 MRS 2279.
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1290 mL | 10.6449 mL | 21.2897 mL | |
5 mM | 0.4258 mL | 2.1290 mL | 4.2579 mL | |
10 mM | 0.2129 mL | 1.0645 mL | 2.1290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.